Acute Interstitial Nephritis With Karyomegalic Epithelial Cells After Nivolumab Treatment—Two Case Reports
Clinical application of immune checkpoint inhibitors (CPIs) including nivolumab is expanding in the field of oncology treatment. Nivolumab is an anti-programmed death 1 protein (PD-1) antibody designed to augment an immunologic reaction against cancer cells. On the contrary, CPIs are known to cause...
Main Authors: | Masaki Ryuzaki, Hirobumi Tokuyama, Kiyotaka Uchiyama, Hideaki Nakaya, Kazuhiro Hasegawa, Kazutoshi Miyashita, Kohnosuke Konishi, Akinori Hashiguchi, Shu Wakino, Hiroshi Itoh |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-06-01
|
Series: | Clinical Medicine Insights: Case Reports |
Online Access: | https://doi.org/10.1177/1179547619853647 |
Similar Items
-
Karyomegalic interstitial nephritis
by: Xhamy Martelli Guerrero, et al.
Published: (2024-09-01) -
Association of karyomegalic interstitial nephritis with focal segmental glomerulosclerosis
by: Momal Tara Chand, et al.
Published: (2021-11-01) -
Karyomegalic interstitial nephritis: diagnosed only when suspected
by: Monica Sivakumar, et al.
Published: (2021-04-01) -
Karyomegalic interstitial nephritis—A rare cause of chronic tubulointerstitial Nephritis
by: Kanishk Gupta, et al.
Published: (2022-01-01) -
New familial cases of karyomegalic interstitial nephritis with mutations in the FAN1 gene
by: Imen Rejeb, et al.
Published: (2021-06-01)